SE0201635D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0201635D0
SE0201635D0 SE0201635A SE0201635A SE0201635D0 SE 0201635 D0 SE0201635 D0 SE 0201635D0 SE 0201635 A SE0201635 A SE 0201635A SE 0201635 A SE0201635 A SE 0201635A SE 0201635 D0 SE0201635 D0 SE 0201635D0
Authority
SE
Sweden
Prior art keywords
novel compounds
useful
formula
relates
present
Prior art date
Application number
SE0201635A
Other languages
English (en)
Inventor
Simon Teague
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201635A priority Critical patent/SE0201635D0/sv
Publication of SE0201635D0 publication Critical patent/SE0201635D0/sv
Priority to TW092114174A priority patent/TW200407305A/zh
Priority to UA20041109794A priority patent/UA79464C2/uk
Priority to PCT/SE2003/000856 priority patent/WO2003101961A1/en
Priority to ES03725970T priority patent/ES2360936T3/es
Priority to BR0311494-5A priority patent/BR0311494A/pt
Priority to EP03725970A priority patent/EP1513812B1/en
Priority to AT03725970T priority patent/ATE501118T1/de
Priority to RU2004135064/04A priority patent/RU2288914C2/ru
Priority to CA002487675A priority patent/CA2487675A1/en
Priority to MXPA04011876A priority patent/MXPA04011876A/es
Priority to AU2003228201A priority patent/AU2003228201A1/en
Priority to US10/516,557 priority patent/US7166607B2/en
Priority to KR10-2004-7019452A priority patent/KR20050010507A/ko
Priority to DE60336314T priority patent/DE60336314D1/de
Priority to NZ536883A priority patent/NZ536883A/en
Priority to JP2004509654A priority patent/JP4485354B2/ja
Priority to PL03375111A priority patent/PL375111A1/xx
Priority to CNB038183447A priority patent/CN100404505C/zh
Priority to MYPI20031973A priority patent/MY133624A/en
Priority to ARP030101932A priority patent/AR039934A1/es
Priority to ZA200409641A priority patent/ZA200409641B/xx
Priority to CO04120052A priority patent/CO5631431A2/es
Priority to IS7607A priority patent/IS7607A/is
Priority to NO20045589A priority patent/NO20045589L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0201635A 2002-05-30 2002-05-30 Novel compounds SE0201635D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds
TW092114174A TW200407305A (en) 2002-05-30 2003-05-26 Novel compounds
CNB038183447A CN100404505C (zh) 2002-05-30 2003-05-27 新的取代吲哚
MXPA04011876A MXPA04011876A (es) 2002-05-30 2003-05-27 Nuevos indoles sustituidos.
KR10-2004-7019452A KR20050010507A (ko) 2002-05-30 2003-05-27 신규 치환 인돌
ES03725970T ES2360936T3 (es) 2002-05-30 2003-05-27 Indoles sustituidos.
BR0311494-5A BR0311494A (pt) 2002-05-30 2003-05-27 Novos indóis substituìdos
EP03725970A EP1513812B1 (en) 2002-05-30 2003-05-27 Substituted indoles
AT03725970T ATE501118T1 (de) 2002-05-30 2003-05-27 Substituierte indole
RU2004135064/04A RU2288914C2 (ru) 2002-05-30 2003-05-27 Новые замещенные индолы
CA002487675A CA2487675A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
UA20041109794A UA79464C2 (en) 2002-05-30 2003-05-27 Substituted indoles, methods for their production and method for treating disorders mediated by prostaglandin d2
AU2003228201A AU2003228201A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
US10/516,557 US7166607B2 (en) 2002-05-30 2003-05-27 Substituted indoles
PCT/SE2003/000856 WO2003101961A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
DE60336314T DE60336314D1 (de) 2002-05-30 2003-05-27 Substituierte indole
NZ536883A NZ536883A (en) 2002-05-30 2003-05-27 Novel substituted indoles
JP2004509654A JP4485354B2 (ja) 2002-05-30 2003-05-27 新規な置換インドール類
PL03375111A PL375111A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
MYPI20031973A MY133624A (en) 2002-05-30 2003-05-28 Thio-substituted indole acetic acid derivatives for the treatment of respiratory disease
ARP030101932A AR039934A1 (es) 2002-05-30 2003-05-30 Indoles sustituidos para el tratamiento de desordenes respiratorios
ZA200409641A ZA200409641B (en) 2002-05-30 2004-11-29 Novel substituted indoles.
CO04120052A CO5631431A2 (es) 2002-05-30 2004-11-29 Indoles sustituidos novedosos
IS7607A IS7607A (is) 2002-05-30 2004-12-21 Ný útskipt indól
NO20045589A NO20045589L (no) 2002-05-30 2004-12-22 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds

Publications (1)

Publication Number Publication Date
SE0201635D0 true SE0201635D0 (sv) 2002-05-30

Family

ID=20288018

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds

Country Status (25)

Country Link
US (1) US7166607B2 (sv)
EP (1) EP1513812B1 (sv)
JP (1) JP4485354B2 (sv)
KR (1) KR20050010507A (sv)
CN (1) CN100404505C (sv)
AR (1) AR039934A1 (sv)
AT (1) ATE501118T1 (sv)
AU (1) AU2003228201A1 (sv)
BR (1) BR0311494A (sv)
CA (1) CA2487675A1 (sv)
CO (1) CO5631431A2 (sv)
DE (1) DE60336314D1 (sv)
ES (1) ES2360936T3 (sv)
IS (1) IS7607A (sv)
MX (1) MXPA04011876A (sv)
MY (1) MY133624A (sv)
NO (1) NO20045589L (sv)
NZ (1) NZ536883A (sv)
PL (1) PL375111A1 (sv)
RU (1) RU2288914C2 (sv)
SE (1) SE0201635D0 (sv)
TW (1) TW200407305A (sv)
UA (1) UA79464C2 (sv)
WO (1) WO2003101961A1 (sv)
ZA (1) ZA200409641B (sv)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
CA2542716A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
RU2387652C2 (ru) 2004-03-11 2010-04-27 Актелион Фармасьютиклз Лтд Производные тетрагидропиридоиндола
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US8022063B2 (en) 2004-05-29 2011-09-20 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
CN101052397B (zh) * 2004-08-26 2011-07-06 埃科特莱茵药品有限公司 2-硫烷基-苯并咪唑-1-基-乙酸衍生物
EP1805171A4 (en) 2004-09-21 2009-05-13 Wyeth Corp CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF
AU2005302706B2 (en) * 2004-10-27 2011-12-15 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
EP1916245B1 (en) * 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
WO2007010965A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US7741360B2 (en) * 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
WO2013142295A1 (en) 2012-03-21 2013-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
PT2046740E (pt) 2006-07-22 2012-08-28 Oxagen Ltd Compostos com atividade antagonista do crth2
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
CA2681409A1 (en) * 2007-03-21 2008-09-25 Argenta Oral Therapeutics Limited Indolizine acetic acid derivatives as crth2 antagonists
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
ES2471919T3 (es) 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2250161E (pt) 2008-01-18 2014-01-21 Atopix Therapeutics Ltd Compostos tendo atividade antagonista de crth2
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
CN102822163B (zh) 2009-12-23 2016-01-20 艾恩伍德医药品股份有限公司 Crth2调节剂
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2011117798A1 (en) 2010-03-22 2011-09-29 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EA026692B1 (ru) 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012064559A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
MY165623A (en) 2011-04-14 2018-04-18 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2012158435A1 (en) * 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
SG11201501360TA (en) * 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK1208465A1 (en) 2012-08-28 2016-03-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
RS63108B1 (sr) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
ES2774749T3 (es) 2013-07-25 2020-07-22 Janssen Sciences Ireland Unlimited Co Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
HRP20181555T1 (hr) 2014-03-17 2018-11-30 Idorsia Pharmaceuticals Ltd Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MX2018001217A (es) 2015-07-30 2018-09-12 Univ Pennsylvania Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2.
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
MA45592A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Promédicaments à base de phosphore de stimulateurs de sgc
EA202092171A1 (ru) 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation DELAYED-RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED PROCEDURES
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
CN114989136A (zh) * 2021-02-02 2022-09-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN114835678A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN114835677B (zh) * 2021-02-02 2025-09-26 广东东阳光药业股份有限公司 吲哚衍生物的盐及其用途
CN115093360B (zh) * 2022-07-06 2023-11-17 都创(上海)医药科技股份有限公司 一种吲哚类衍生物的合成方法
CN117205206A (zh) * 2023-08-16 2023-12-12 江南大学 一种能改善哮喘小鼠病理特征的色氨酸代谢物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPS5239671A (en) * 1975-09-22 1977-03-28 Sankyo Co Ltd Process for preparing indole-3-thioether compounds
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) * 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AU6165894A (en) 1993-01-28 1994-08-15 Trustees Of The University Of Pennsylvania, The Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
BR9405737A (pt) * 1993-02-24 1995-12-05 Merck & Co Inc Composto processo de inibição de transcriptase reserva de HIV, processo de prevenção contra a infecção pelo HIV ou de tratamento da infecção pelo HIV, composição farmacêutica útil para a inibição da transcriptase reserva de HIV, e, útil para a prevenção ou tratamento de infecção pelo HIV ou para o tratamento da AIDS ou ARC
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017256A1 (es) 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
WO1999032482A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
BR0307406A (pt) 2002-02-01 2004-12-28 Hoffmann La Roche Indóis substituìdos como agonistas alfa-1
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1513812A1 (en) 2005-03-16
CA2487675A1 (en) 2003-12-11
WO2003101961A1 (en) 2003-12-11
AU2003228201A1 (en) 2003-12-19
EP1513812B1 (en) 2011-03-09
PL375111A1 (en) 2005-11-28
KR20050010507A (ko) 2005-01-27
CN1671659A (zh) 2005-09-21
CN100404505C (zh) 2008-07-23
ZA200409641B (en) 2006-02-22
CO5631431A2 (es) 2006-04-28
MXPA04011876A (es) 2005-03-31
UA79464C2 (en) 2007-06-25
TW200407305A (en) 2004-05-16
IS7607A (is) 2004-12-21
NO20045589L (no) 2005-02-02
ATE501118T1 (de) 2011-03-15
NZ536883A (en) 2006-08-31
US7166607B2 (en) 2007-01-23
US20050165055A1 (en) 2005-07-28
RU2288914C2 (ru) 2006-12-10
JP4485354B2 (ja) 2010-06-23
ES2360936T3 (es) 2011-06-10
RU2004135064A (ru) 2005-08-10
MY133624A (en) 2007-11-30
BR0311494A (pt) 2005-03-29
JP2005538955A (ja) 2005-12-22
AR039934A1 (es) 2005-03-09
DE60336314D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
SE0201635D0 (sv) Novel compounds
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
SE0202241D0 (sv) Novel Compounds
TW200510301A (en) Novel compounds
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
TW200503724A (en) Novel pharmaceuticals
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200728258A (en) Novel compounds
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
MXPA05011289A (es) Compuestos de fosfato que tienen actividad inmunomoduladora.
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
GB0215392D0 (en) Chemical compounds
GB0519760D0 (en) Novel compounds